ARTICLE | Clinical News
Cilengitide: Completed Phase III enrollment
June 13, 2011 7:00 AM UTC
Merck's EMD Serono Inc. affiliate completed enrollment of >500 newly diagnosed GBM patients with a methylated methylguanine- DNA methyltransferase ( MGMT) gene promoter in the open-label, internationa...